Life-Threatening Myositis in a Patient With EGFR-Mutated NSCLC on Osimertinib: Case Report

Life-Threatening Myositis in a Patient With EGFR-Mutated NSCLC on Osimertinib: Case Report

Osimertinib is the standard of care for the first-line treatment of EGFR-mutated NSCLC. We report a case of a 52-year-old woman who developed life-threatening myopathy because of treatment with osimertinib. Limited instances of myositis have been previously reported in the literature; however, none...

Full description

Bibliographic Details
Main Authors: Fionnuala Crowley, MB BCh BAO, Bailey G. Fitzgerald, MD, Aarti S. Bhardwaj, MD, Irine Siraj, MD, Cardinale Smith, MD, PhD
Format: Article
Language:English
Published: Elsevier 2022-01-01
Series:JTO Clinical and Research Reports
Subjects:
Osimertinib
Myositis
NSCLC
EGFR
Case report
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364321001193

Internet

http://www.sciencedirect.com/science/article/pii/S2666364321001193

Similar Items